- Home
- BTMD vs IVA Comparison
BTMD vs IVA Comparison
Compare BTMD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- IVA
- Stock Information
- Founded
- BTMD 2012
- IVA 2011
- Country
- BTMD United States
- IVA France
- Employees
- BTMD N/A
- IVA N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- IVA Health Care
- Exchange
- BTMD Nasdaq
- IVA Nasdaq
- Market Cap
- BTMD 136.0M
- IVA 162.8M
- IPO Year
- BTMD N/A
- IVA 2020
- Fundamental
- Price
- BTMD $3.36
- IVA $3.20
- Analyst Decision
- BTMD Strong Buy
- IVA Strong Buy
- Analyst Count
- BTMD 1
- IVA 4
- Target Price
- BTMD $8.00
- IVA $13.25
- AVG Volume (30 Days)
- BTMD 324.0K
- IVA 8.7K
- Earning Date
- BTMD 05-06-2025
- IVA 03-26-2025
- Dividend Yield
- BTMD N/A
- IVA N/A
- EPS Growth
- BTMD N/A
- IVA N/A
- EPS
- BTMD 0.09
- IVA N/A
- Revenue
- BTMD $197,191,000.00
- IVA $15,243,814.00
- Revenue This Year
- BTMD $6.20
- IVA $18.05
- Revenue Next Year
- BTMD $9.24
- IVA $46.74
- P/E Ratio
- BTMD $37.44
- IVA N/A
- Revenue Growth
- BTMD 6.38
- IVA N/A
- 52 Week Low
- BTMD $3.04
- IVA $1.53
- 52 Week High
- BTMD $8.44
- IVA $3.98
- Technical
- Relative Strength Index (RSI)
- BTMD 37.19
- IVA 61.75
- Support Level
- BTMD $3.21
- IVA $2.88
- Resistance Level
- BTMD $3.65
- IVA $3.10
- Average True Range (ATR)
- BTMD 0.28
- IVA 0.18
- MACD
- BTMD -0.01
- IVA 0.01
- Stochastic Oscillator
- BTMD 11.90
- IVA 77.39
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.